Dr. Yael Mossé receives recognition for project dedicated to researching and potentially developing new therapies for undruggable solid tumors.
Identifying “backbones” that link complexes can help maximize CAR therapy across different variants and tumor types.
Currently nestled in the Department of Pathology on the fifth floor of the Main Hospital at Children's Hospital of Philadelphia, the Cell and Gene Therapy Laboratory (CGTL) is poised to emerge in big way throughout 2024 and beyond as they expand their facilities to keep up with the pace of discovery in cell and gene therapy.
The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
Children’s Hospital of Philadelphia is proud to announce the initial results of an experimental gene therapy treatment of a patient with hereditary hearing loss in the United States. Findings to date indicate that the treatment was successful.
Children’s Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma. This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.
It’s an exciting time for research in the bronchopulmonary dysplasia (BPD) population here at Children’s Hospital of Philadelphia (CHOP).
This new method, typically used in adult patients, may spare patients from having to undergo open heart surgery.
This case study describes a 10-year-old boy with acute, then chronic, pancreatitis and what CHOP did to treat his condition and improve his quality of life.